Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 4, 2013, Pages 376-382

  Sun, Hai Bo ^a   Ou, Wei ^b   Li, Yin ^a   Fang, Qin ^c   Qin, Jianjun ^a   Zhang, Liang ^b   Wang, Si Yu ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Third People's Hospital of Huizhou   (China)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Non small cell lung cancer; Prognostic marker

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MUTATION; NEOPLASM STAGING; PACLITAXEL; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; VINBLASTINE;

EID: 84878773673     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.10.008     Document Type: Article

References (28)

1. D.R. Youlden, S.M. Cramb, P.D. Baade The international epidemiology of lung cancer: geographical distribution and secular trends J Thorac Oncol 3 2008 819 831
2. C.F. Mountain Revisions in the International System for Staging Lung Cancer Chest 111 1997 1710 1717
3. R. Arriagada, B. Bergman, A. Dunant Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
4. J.Y. Douillard, R. Rosell, M. De Lena Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727
5. J.P. Pignon, H. Tribodet, G.V. Scagliotti Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
6. T. Winton, R. Livingston, D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
7. W. Ou, H.B. Sun, X. Ye Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer J Thorac Oncol 5 2010 1033 1041
8. Z. Sun, M.C. Aubry, C. Deschamps Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases J Thorac Cardiovasc Surg 131 2006 1014 1020
9. K.A. Olaussen, A. Dunant, P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
10. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
11. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
12. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
13. T. Le Chevalier Results of the randomized international adjuvant lung cancer trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients with resected non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 6 2003 1423 1425
14. K. Endo, A. Konishi, H. Sasaki Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay Lung Cancer 50 2005 375 384
15. S. Huang, F. Liu, Z. Sha Effect of high glucose, angiotensin II and receptor antagonist losartan on the expression of connective tissue growth factor in cultured mesangial cells Chin Med J (Engl) 116 2003 554 557
16. H.B. Sun, Y. Zheng, W. Ou Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer Ann Thorac Surg 91 2011 1562 1567
17. H. Suehisa, S. Toyooka, K. Hotta Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung J Clin Oncol 25 2007 3952 3957
18. S. Murray, E. Timotheadou, H. Linardou Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients Lung Cancer 52 2006 225 233
19. H.P. Liu, H.D. Isaac Wu, J.W. Chang Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan J Thorac Oncol 5 2010 1175 1184
20. M.S. Tsao, A. Sakurada, K. Ding Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer J Thorac Oncol 6 2011 139 147
21. J.L. Marks, S. Broderick, Q. Zhou Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
22. J.Y. Douillard, F.A. Shepherd, V. Hirsh Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 2010 744 752
23. C.Q. Zhu, G. da Cunha Santos, K. Ding Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21 J Clin Oncol 26 2008 4268 4275
24. D.A. Eberhard, B.E. Johnson, L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
25. R.I. Nicholson, J.M. Gee, M.E. Harper EGFR and cancer prognosis Harper, ME Eur J Cancer 37 suppl 4 2001 S9 S15
26. M.B. Resnick, J. Routhier, T. Konkin Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study Clin Cancer Res 10 2004 3069 3075
27. R.S. Herbst Review of epidermal growth factor receptor biology Int J Radiat Oncol Biol Phys 59 suppl 2 2004 21 26
28. J.W. Neal, N.A. Pennell, R. Govindan The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstract 7010